Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 412 across all filing types
Latest filing 2022-07-06 Regulatory Filings
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Sehr erfolgreicher Start fur Vermarktungsaktion mit Drogeriemarktkette dm
Regulatory Filings Classification · 100% confidence The document is a news release dated July 6, 2022, originating from NanoRepro AG, distributed via DGAP (a service often used for regulatory news in Germany). The content details a successful marketing promotion with the drugstore chain 'dm' regarding the placement and initial sales success of various self-tests. It is an announcement about a business development and sales update, not a formal financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing like insider trading (DIRS) or dividend notice (DIV). Since it is a general corporate news announcement regarding business operations and sales performance, and it is not a formal financial report, it fits best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate announcement, although it shares characteristics with an Earnings Release (ER) by providing performance highlights. Given the structure (News Details, DGAP-News header, focus on a specific marketing campaign success rather than comprehensive period results), RNS is the most appropriate fallback for non-standard corporate news releases that aren't explicitly defined elsewhere.
2022-07-06 German
Jahresabschluss 2021
Annual Report Classification · 100% confidence The document is titled 'Jahresabschluss' (Annual Financial Statement) and 'Geschäftsbericht 2021' (Annual Report 2021) for NanoRepro AG. It contains comprehensive sections including the Report of the Supervisory Board, Management Report (Lagebericht), Balance Sheet, Profit and Loss Statement, and Auditor's Report. Given the length and the inclusion of full financial statements and management analysis for the fiscal year 2021, it is classified as an Annual Report (10-K). FY 2021
2022-06-13 German
Drogeriemarktkette dm: Vermarktungsaktion fur NanoRepro-Produkte in 2000 Filialen
Regulatory Filings Classification · 100% confidence The document is a short news release dated May 11, 2022, announcing a commercial cooperation between NanoRepro AG and the drugstore chain 'dm' regarding the placement of various self-tests in over 2,000 stores starting in July 2022. It is explicitly labeled as 'DGAP-News' and distributed via the DGAP service, which handles corporate news and regulatory announcements. Since this is an announcement about a business development/cooperation and not a mandatory financial filing (like 10-K, IR, ER, or DIV), and it is short, it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it doesn't fit the more specific operational or financial report codes. It is not a Report Publication Announcement (RPA) because it is announcing a business event, not the publication of a financial report itself.
2022-05-11 German
NanoRepro AG tritt in Milliarden-Oligopol-Markt Diabetes-Diagnostik ein
Regulatory Filings Classification · 100% confidence The document is a press release dated April 13, 2022, announcing a significant business development for NanoRepro AG: entering the diabetes diagnostics market via a licensing agreement for a Continuous Glucose Monitoring (CGM) system. It details the contract, market growth projections, and strategic plans. This type of announcement, focusing on a major contract, market entry, and strategic partnership, aligns best with a general corporate news release that isn't strictly an earnings release (ER), a formal financial report (10-K or IR), or a specific insider transaction (DIRS). Since it announces a major strategic move and potential future revenue streams, it is a significant corporate event announcement. Given the options, it is a general corporate announcement. It is not a formal regulatory filing like a 10-K or IR, nor is it a short announcement pointing to another document (RPA/RNS). It is a detailed news item about a contract and market expansion. This fits best under the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-standard announcements, or potentially 'Capital/Financing Update' (CAP) if the focus was purely on the deal structure, but here the focus is on the business expansion itself. However, since it is a detailed news item about a contract and market entry, and not a standard financial report, RNS is the most appropriate fallback for a significant corporate news item that doesn't fit the other specific categories like DIV, DIRS, or ER.
2022-04-13 German
NanoRepro AG: Antigen-Schnelltests auf PEI-Liste zur Erkennung von Omikron
Regulatory Filings Classification · 100% confidence The document is a short news release dated March 25, 2022, from NanoRepro AG, announcing that their antigen rapid tests have been validated by the Paul-Ehrlich-Institut (PEI) for detecting the Omicron variant. It contains key highlights, company background, and contact information, but it is not a comprehensive financial report (like 10-K or IR) nor is it a transcript or a formal regulatory filing like a DEF 14A or DVA. The structure strongly suggests an initial announcement of operational/product news. Since it is a news item about a specific event/result (test validation) and not a general regulatory filing fallback (RNS) or a formal earnings release (ER), it fits best under the general Regulatory Filings (RNS) category as a miscellaneous corporate announcement, or potentially an Earnings Release (ER) if the validation is considered a key performance indicator announcement, but RNS is safer for non-financial operational news distributed via DGAP/EQS.
2022-03-25 German
NanoRepro AG: Jahresabschluss 2021 - Umsatz und Gewinn steigen auf das Zehnfache
Earnings Release Classification · 100% confidence The document is titled 'NanoRepro AG: Jahresabschluss 2021 – Umsatz und Gewinn steigen auf das Zehnfache' (Annual Financial Statements 2021). It explicitly states that the company 'hat heute den testierten Jahresabschluss 2021 veröffentlicht' (has today published the audited annual financial statements 2021). It provides detailed financial metrics for the full year 2021 (Revenue, EBITDA, Net Income, EPS) and mentions a proposed dividend. Although it is an announcement about the financial results, the content is a summary of the full annual performance, which strongly aligns with the content of an Annual Report (10-K equivalent for a German company, though 10-K is the specific SEC code). Since the text provides the core results and mentions the full report is available via a link, it functions as the primary release of the annual performance data. Given the options, '10-K' is the closest fit for a comprehensive annual financial report summary, even if it's a German equivalent, as it covers the full fiscal year performance and is audited ('testierten'). It is not just an Earnings Release (ER) as it covers the full year and is explicitly called the 'Jahresabschluss' (Annual Financial Statements). FY 2021
2022-03-21 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.